Pharmacogenetic aspects of oral hypoglycemic therapy. Response and failure phenotypes

Abstract

The research work attempted to answer the question whether an effective personalized glucose-lowering therapy, particularly with metformin, is possible in patients with type 2 diabetes based on single nucleotide polymorphism of the three genes (endothelial nitric oxide synthase, 8-oxoguanine DNA glycosylase and p53). Metformin efficacy could depend, in particular, on the presence of polymorphism in these genes.

Keywords

• фармакогенетика
• метформин фенотип «провала»
• фенотип «ответа»
• персонифицированная медицина
• pharmacogenetics
• metformin
• failure phenotype
• response phenotype
• personalized medicine